Association of activated c-Met with NRAS-mutated human melanomas. - Wikidata - awgldk - TriplyDB

Association of activated c-Met with NRAS-mutated human melanomas.

Association of activated c-Met with NRAS-mutated human melanomas.

http://www.wikidata.org/entity/Q35914680

about

Other targeted drugs in melanoma Characteristics of lung cancers harboring NRAS mutations Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma Driver mutations in melanoma: lessons learned from bench-to-bedside studies Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.Mutational status of naevus-associated melanomas.Ultraviolet Radiation-Induced Cytogenetic Damage in White, Hispanic and Black Skin Melanocytes: A Risk for Cutaneous Melanoma.Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.Plexin B1 inhibits MET through direct association and regulates Shp2 expression in melanocytes SHP2 phosphatase as a novel therapeutic target for melanoma treatment.Targeted therapy for melanoma: rational combinatorial approaches.Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways.Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma.MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention.

P2860

Q26775594-6D24C841-DDC6-4C21-9E70-B9021B528588 Q28706226-C558D22A-71E7-47AE-A324-D0F83DF7FCFD Q28730438-4A915E98-A040-422F-A6ED-DE66153F178F Q34459058-BD403D7B-BA04-4E45-8F27-DC02CB3C7526 Q34639532-41B04AC2-281D-40BC-A11D-0CBEE375848B Q34964958-9C305E27-557F-464B-A6EA-177812DD0B56 Q35097186-C90EE7C2-72A8-4AA4-B745-F81B32967A13 Q35320304-A06CA9A4-860D-40CD-AA99-DCB3D96987E0 Q36095004-1F8C5429-01E3-4EB0-8D9A-FDF01EBCAC8B Q36102856-0EB3B0D0-915F-48A6-821B-8678BEBB4FE0 Q36260662-03815AA8-91E6-4988-9141-8537090D0C9A Q36731467-A1323D4A-B768-44F8-8E17-BA90151F2004 Q37687479-B61CA4DC-2ABE-4705-899E-3D19BD028D4F Q38082327-8A579A81-76DD-4CAA-A92C-736A25ED1C35 Q38755819-8C48F2F6-9349-4FEC-97D3-CB6C22C0A827 Q38875292-A78AD801-6FD0-4A90-9796-D6EEB37B6915 Q38986202-C1AD72D6-99BF-44C7-87D1-27A7265462D0 Q39412894-DF67AC7A-2542-439F-AD69-667AED03D73B Q39434922-C654F7CD-44B1-435D-AED5-8EA72177F5BB Q42290800-4C2D2411-8DAA-4543-94F6-D2989672C597 Q47595971-DE42BECA-4722-4BBE-9787-9274E1E04238 Q49887930-C91F6261-EAEC-415A-8B62-0728653DE4CC Q50062795-1271D42D-186A-40BC-BA20-3D677016B643

P2860

Association of activated c-Met with NRAS-mutated human melanomas.

http://www.wikidata.org/entity/Q35914680

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Association of activated c-Met with NRAS-mutated human melanomas.

@ast

Association of activated c-Met with NRAS-mutated human melanomas.

@en

type

label

Association of activated c-Met with NRAS-mutated human melanomas.

@ast

Association of activated c-Met with NRAS-mutated human melanomas.

@en

prefLabel

Association of activated c-Met with NRAS-mutated human melanomas.

@ast

Association of activated c-Met with NRAS-mutated human melanomas.

@en

P1433

Q35914680-546CE7CD-9FF7-45F8-9D56-75925E9AC03D

P1476

Q35914680-15273712-B0CC-4021-88EE-5B25CA2615BA

P2093

Q35914680-48F43B15-8746-4BEF-88F2-E7709AA79ECC

Q35914680-57833E20-D0C2-455C-98B5-02227D3C4FD1

Q35914680-67845D3D-8038-4C17-92F2-AD8F57B3FFA9

Q35914680-6BB0A2F6-A880-4F4A-A3C2-0B34F23D3D16

Q35914680-73E9372B-69D2-4D67-BDC1-2E809BCAA90C

Q35914680-79AD0A81-9611-438D-8984-6D47EC6E08A7

P2860

Q35914680-057702BE-7BCB-45D4-A9DF-913C949E401A

Q35914680-079D31C6-709B-4390-B0B8-3990165FE91B

Q35914680-10BE6B00-3F1B-43F1-9569-F6137ACA11CF

Q35914680-202F8575-7511-4E92-8551-82EE30ADFE7C

Q35914680-20E5A52B-5016-436E-862A-C1FCAF5B455F

Q35914680-24212DD3-4FD7-4E57-AA72-D26602C091C3

Q35914680-2B7D08A1-E176-450F-A6F2-7D5153C1F9A2

Q35914680-2EF40C8F-0666-4E77-8A42-94C0951CDD71

Q35914680-3FE78749-AF71-4210-A2D0-1EBBD3E97B70

Q35914680-40A67D47-2CF0-4AFD-8B56-20B76C632A28

P304

Q35914680-8EAB198D-B137-4CB0-94A5-30BFF5CB5402

P31

Q35914680-C6E79470-9DA1-4208-B46E-71733483B161

P356

Q35914680-0DD3A68A-0E49-4E4D-AC2A-A4E843A8CA06

P433

Q35914680-035FC160-C259-4E78-BFA2-43889C26C93D

P478

Q35914680-8343C9DF-F0D3-4541-BD1A-0281EB199E3F

P577

Q35914680-AF1042FA-33CD-49B3-A60E-BA3B41F11ED7

P5875

Q35914680-AE9D0D61-C9F3-4E0C-ACD3-3476D2916785

P698

Q35914680-C8EA5067-E16A-4BF4-A3AA-02A4B76DF756

P932

Q35914680-8347035C-2520-4482-AAF2-F3965C4F4F37

P356

P1433

International Journal of Cancer

P1476

Association of activated c-Met with NRAS-mutated human melanomas.

@en

P2093

Chandrani Chattopadhyay

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Grimm

http://www.w3.org/2001/XMLSchema#string

Julie A Ellerhorst

http://www.w3.org/2001/XMLSchema#string

Michael A Davies

http://www.w3.org/2001/XMLSchema#string

Suhendan Ekmekcioglu

http://www.w3.org/2001/XMLSchema#string

Victoria R Greene

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of the genome to personalize therapy for melanoma

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Met receptor tyrosine kinase: enhanced signaling through adapter proteins

Targeting the c-Met signaling pathway in cancer

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas.

Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines.

P304

E56-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.26487

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51742172

http://www.w3.org/2001/XMLSchema#string

P698

22020736

http://www.w3.org/2001/XMLSchema#string

P932

3337366

http://www.w3.org/2001/XMLSchema#string